Literature DB >> 25194075

Possible impact of comorbid conditions on the persistence of nocturnal enuresis: results of a long-term follow-up study.

Pietro Ferrara1, Maria Chiara De Angelis2, Olga Caporale2, Monica Malamisura2, Valentina Del Volgo2, Flaminia Vena2, Antonio Gatto3, Antonio Chiaretti3.   

Abstract

PURPOSE: To describe the natural history of patients with nocturnal enuresis (NE) during a 10-year period and to evaluate possible impact of comorbid conditions on the persistence of NE.
MATERIALS AND METHODS: Ninety-five children (male to female ratio [M:F] 65:30), aged at first visit between 6 and 21 years were included in this study. Of study subjects 75 had primary monosymptomatic nocturnal enuresis (PMNE), 3 had secondary monosymptomatic nocturnal enuresis (SMNE) and 17 had non-mono­symptomatic nocturnal enuresis (NMNE). Demographic and NE-related details were assessed from electron­ic medical records and by telephone interview at the times 3, 6, 12 months and 3, 5, 10 years after the first examination. Sixty-seven of 95 patients were enrolled, of whom 57 had PMNE (M:F ratio 39:18, mean age 9.35 ± 2.81 years, mean age at improvement 11.5 ± 4.08 years), 8 had NMNE (M:F ratio 4:4, mean age 10.1 ± 2.64 years, mean age at improvement 12.6 ± 1.68 years) and 2 had SMNE (M:F ratio 1:1, mean age 12 years, mean age at improvement 13.5 ± 2.12 years).
RESULTS: The mean duration of follow up was 7.2 ± 2.5 years. All of the 67 children had 5 years follow up. Only 29 of 67 patients (19 with PMNE, 8 with NMNE and 2 with SMNE) had 10 years follow up and 4 of 19 with PMNE were still affected by NE. Out of 57 patients with PMNE 12 (2/12 with language disorders, 1/12 varicocele and 1/12 cryptorchidism) and out of 8 patients with NMNE 1 were still enuretic while all patients with SMNE were in remission.
CONCLUSION: We observed that language disorders and testicular pathology in NE children could be comor­bidities associated with persistence of NE and treatment resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25194075

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  7 in total

1.  Innocent heart murmurs and enuresis: Examining a possible link.

Authors:  Pietro Ferrara; Federica Di Ruscio; Margherita Zona; Antonio Ruggiero
Journal:  Turk J Urol       Date:  2019-02-04

2.  The impact of motivational therapy in the management of enuretic children.

Authors:  Pietro Ferrara; Maria Elisa Amodeo; Annamaria Sbordone; Francesca Ianniello; Alberto Verrotti; Tommaso Petitti; Antonio Ruggiero
Journal:  Turk J Urol       Date:  2018-07

3.  Melatonin's Effect on the Efficacy of Desmopressin in the Treatment of Enuresis.

Authors:  Pietro Ferrara; Annamaria Sbordone; Costanza Cutrona; Francesca Ianniello; Chiara Guadagno; Giacomo Perrone; Antonio Chiaretti; Alberto Verrotti; Vincenzo Di Lazzaro
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

4.  A Possible Pathogenic Linkage Among Headache, Migraine, and Nocturnal Enuresis in Children.

Authors:  Pietro Ferrara; Livia Dell'Aquila; Giacomo Perrone; Giulia Spina; Francesco Miconi; Valentina Rapaccini; Ester Del Vescovo; Vincenzo Di Lazzaro; Alberto Verrotti
Journal:  Int Neurourol J       Date:  2016-12-26       Impact factor: 2.835

5.  Gambling disorder in adolescents: what do we know about this social problem and its consequences?

Authors:  Pietro Ferrara; Giulia Franceschini; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2018-12-04       Impact factor: 2.638

6.  Medical Comorbidity of Nocturnal Enuresis in Children.

Authors:  Pietro Ferrara; Roberta Autuori; Flavia Dosa; Alessandro Di Lucia; Antonio Gatto; Antonio Chiaretti
Journal:  Indian J Nephrol       Date:  2019 Sep-Oct

7.  The adverse effects of oral desmopressin lyophilisate (MELT): personal experience on enuretic children.

Authors:  Pietro Ferrara; Giulia Franceschini; Serena Mercurio; Ester Del Vescovo; Francesca Ianniello; Tommasangelo Petitti
Journal:  Turk J Urol       Date:  2018-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.